The Law Offices of Frank R. Cruz Announces Investigation of Fulgent Genetics, Inc. (FLGT) on Behalf of Investors

LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz announces an investigation of Fulgent Genetics, Inc. (“Fulgent” or the “Company”) (NASDAQ: FLGT) on behalf of investors concerning the Company’s possible violations of federal securities laws.

If you are a shareholder who suffered a loss, click here to participate.

On August 4, 2022, Fulgent released its second quarter 2022 financial results, disclosing that the SEC is conducting an investigation into certain Exchange Act reports for 2018 through the first quarter of 2020. This comes after the Company received a civil investigative demand issued by the U.S. Department of Justice “related to its investigation of allegations of medically unnecessary laboratory testing, improper billing for laboratory testing, and remuneration received or provided in violation of the Anti-Kickback Statute and the Stark Law.”

On this news, Fulgent’s stock fell as much as 8% during intraday trading on August 5, 2022, thereby injuring investors.

Follow us for updates on Twitter: twitter.com/FRC_LAW.

If you purchased Fulgent securities, have information or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Frank R. Cruz, of The Law Offices of Frank R. Cruz, 1999 Avenue of the Stars, Suite 1100, Los Angeles, California 90067 at 310-914-5007, by email to [e-mail], or visit our website at www.frankcruzlaw.com. If you inquire by email please include your mailing address, telephone number, and number of shares purchased.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.